Skip to main content

Advertisement

SpringerLink
Log in

Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

  • Review Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

The monoclonal antibody market continues to witness an impressive rate of growth and has become the leading source of expansion in the biologic segment within the pharmaceutical industry. Currently marketed monoclonal antibodies target a diverse array of antigens. These antigens are distributed in a variety of tissues such as tumors, lungs, synovial fluid, psoriatic plaques, and lymph nodes. As the concentration of drug at the proximity of the biological receptor determines the magnitude of the observed pharmacological responses, a significant consideration in effective therapeutic application of monoclonal antibodies is a thorough understanding of the processes that regulate antibody biodistribution. Monoclonal antibody distribution is affected by factors such as molecular weight, blood flow, tissue and tumor heterogeneity, structure and porosity, target antigen density, turnover rate, and the target antigen expression profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Humira. Prescribing Information: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_02_B-Abbott-Humira%20Prescribing%20Info.pdf. 2009.

  2. Mascelli MA, Zhou H, Sweet R, Getsy J, Davis HM, Graham M, et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007;47(5):553–65.

    CAS  PubMed  Google Scholar 

  3. Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-{alpha} human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49(9):1056–70.

    CAS  PubMed  Google Scholar 

  4. Nestorov I, Zitnik R, DeVries T, Nakanishi AM, Wang A, Banfield C. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol. 2006;62(4):435–45.

    CAS  PubMed  Google Scholar 

  5. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol. 2005;45(5):490–7.

    CAS  PubMed  Google Scholar 

  6. Tomlinson IM. Next-generation protein drugs. Nat Biotechnol. 2004;22(5):521–2.

    CAS  PubMed  Google Scholar 

  7. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039–51.

    CAS  PubMed  Google Scholar 

  8. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6(4):559–93.

    CAS  PubMed  Google Scholar 

  9. Jain RK, Gerlowski LE. Extravascular transport in normal and tumor tissues. Crit Rev Oncol Hematol. 1986;5(2):115–70.

    CAS  PubMed  Google Scholar 

  10. Tabrizi M, Roskos LK. Exposure–response relationships for therapeutic biologic products. In: Meibohem B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs. Wiley: New York; 2006. p. 295–327.

    Google Scholar 

  11. Tabrizi M, Suria H. Application of translational biomarkers in development of antibody-based therapeutics. Drug Discov. 2009;5(1): 2–6.

    Google Scholar 

  12. Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today. 2009;14(5–6):298–305.

    CAS  PubMed  Google Scholar 

  13. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1–2):81–8.

    CAS  PubMed  Google Scholar 

  14. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–68.

    CAS  PubMed  Google Scholar 

  15. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56(3):248–52.

    CAS  PubMed  Google Scholar 

  16. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32.

    CAS  PubMed  Google Scholar 

  17. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today. 2007;12(21–22):898–910.

    CAS  PubMed  Google Scholar 

  18. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24(1):19–28.

    CAS  PubMed  Google Scholar 

  19. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275–90.

    CAS  PubMed  Google Scholar 

  20. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50(3 Suppl):814s–9s.

    CAS  PubMed  Google Scholar 

  21. Weinstein JN, van Osdol W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol. 1992;14(3):457–63.

    CAS  PubMed  Google Scholar 

  22. Clauss MA, Jain RK. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. 1990;50(12):3487–92.

    CAS  PubMed  Google Scholar 

  23. Hawkins BT, Davis TP. The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–85.

    CAS  PubMed  Google Scholar 

  24. Gibaldi M, Koup JR. Pharmacokinetic concepts—drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol. 1981;20(4):299–305.

    CAS  PubMed  Google Scholar 

  25. Brambell FW. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet. 1966;2(7473):1087–93.

    CAS  PubMed  Google Scholar 

  26. Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today. 1997;18(12):592–8.

    CAS  PubMed  Google Scholar 

  27. Waldmann TA. Variations in the metabolism of immunoglobulins measured by turnover rates. In: Merler E, editor. Immunoglobulins: biological aspects and clinical uses. Washington, DC: National Academy of Sciences; 1970. p. 33–51.

    Google Scholar 

  28. Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood. 2001;98(10):3136–42.

    CAS  PubMed  Google Scholar 

  29. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood. 2002;100(6):2087–93.

    CAS  PubMed  Google Scholar 

  30. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687–709.

    CAS  PubMed  Google Scholar 

  31. de Haas M. IgG-Fc receptors and the clinical relevance of their polymorphisms. Wien Klin Wochenschr. 2001;113(20–21):825–31.

    PubMed  Google Scholar 

  32. Rascu A, Repp R, Westerdaal NA, Kalden JR, van de Winkel JG. Clinical relevance of Fc gamma receptor polymorphisms. Ann N Y Acad Sci. 1997;815:282–95.

    CAS  PubMed  Google Scholar 

  33. Woof JM, Burton DR. Human antibody–Fc receptor interactions illuminated by crystal structures. Nat Rev. 2004;4(2):89–99.

    CAS  Google Scholar 

  34. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19(3):851–6.

    CAS  PubMed  Google Scholar 

  35. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63(5):548–61.

    CAS  PubMed  Google Scholar 

  36. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18(2):157–62.

    CAS  PubMed  Google Scholar 

  37. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;354(25):2689–95.

    CAS  PubMed  Google Scholar 

  38. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S12–7.

    CAS  PubMed  Google Scholar 

  39. Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341(26):1966–73.

    CAS  PubMed  Google Scholar 

  40. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34(33):10474–82.

    CAS  PubMed  Google Scholar 

  41. Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J. 2008;10(2):425–30.

    CAS  PubMed  Google Scholar 

  42. Johansson SG, Haahtela T, O'Byrne PM. Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol. 2002;89(2):132–8.

    Article  CAS  PubMed  Google Scholar 

  43. Johansson A, Erlandsson A, Eriksson D, Ullen A, Holm P, Sundstrom BE, et al. Idiotypic–anti-idiotypic complexes and their in vivo metabolism. Cancer. 2002;94(4 Suppl):1306–13.

    CAS  PubMed  Google Scholar 

  44. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 2009;24(2):155–61.

    CAS  PubMed  Google Scholar 

  45. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421–34.

    CAS  PubMed  Google Scholar 

  46. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29(2):57–61.

    CAS  PubMed  Google Scholar 

  47. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med. 2007;48(6):995–9.

    CAS  PubMed  Google Scholar 

  48. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63(6):1288–96.

    CAS  PubMed  Google Scholar 

  49. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271(1):58–65.

    Article  CAS  PubMed  Google Scholar 

  50. Jain RK. The Eugene M, Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation. 1997;4(1):1–23.

    CAS  PubMed  Google Scholar 

  51. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002;2(4):266–76.

    CAS  PubMed  Google Scholar 

  52. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000;60(16):4324–7.

    CAS  PubMed  Google Scholar 

  53. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806–13.

    CAS  PubMed  Google Scholar 

  54. Milosevic MF, Fyles AW, Wong R, Pintilie M, Kavanagh MC, Levin W, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer. 1998;82(12):2418–26.

    CAS  PubMed  Google Scholar 

  55. Hori K, Suzuki M, Tanda S, Saito S. In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res. 1990;81(3):279–88.

    CAS  PubMed  Google Scholar 

  56. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150(3):815–21.

    CAS  PubMed  Google Scholar 

  57. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays. 1991;13(1):31–6.

    CAS  PubMed  Google Scholar 

  58. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002;62(18):5381–5.

    CAS  PubMed  Google Scholar 

  59. McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev. 2000;19(1–2):109–20.

    CAS  PubMed  Google Scholar 

  60. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002;160(3):985–1000.

    PubMed  Google Scholar 

  61. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.

    CAS  PubMed  Google Scholar 

  62. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol. 1999;237:97–132.

    CAS  PubMed  Google Scholar 

  63. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156(4):1363–80.

    CAS  PubMed  Google Scholar 

  64. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95(8):4607–12.

    CAS  PubMed  Google Scholar 

  65. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9):987–9.

    CAS  PubMed  Google Scholar 

  66. Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003;9(6):796–800.

    CAS  PubMed  Google Scholar 

  67. Davies C de L, Berk DA, Pluen A, Jain RK. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer. 2002;86(10):1639–44.

    CAS  Google Scholar 

  68. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60(9):2497–503.

    CAS  PubMed  Google Scholar 

  69. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–9.

    CAS  PubMed  Google Scholar 

  70. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49(16):4373–84.

    CAS  PubMed  Google Scholar 

  71. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9(3):253–66.

    CAS  PubMed  Google Scholar 

  72. Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998;178(6):1555–61.

    CAS  PubMed  Google Scholar 

  73. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008;317:103–23.

    CAS  PubMed  Google Scholar 

  74. Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108(2):250–7.

    CAS  PubMed  Google Scholar 

  75. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514–24.

    PubMed  Google Scholar 

  76. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652–65.

    CAS  PubMed  Google Scholar 

  77. Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol. 2005;350(1):126–44.

    CAS  PubMed  Google Scholar 

  78. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006;54(4):1122–31.

    CAS  PubMed  Google Scholar 

  79. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103(9):1345–52.

    CAS  PubMed  Google Scholar 

  80. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double- blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84.

    CAS  PubMed  Google Scholar 

  81. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87–113.

    CAS  PubMed  Google Scholar 

  82. Westacott CI, Barakat AF, Wood L, Perry MJ, Neison P, Bisbinas I, et al. Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis. Osteoarthr Cartil. 2000;8(3):213–21.

    CAS  PubMed  Google Scholar 

  83. Choy EH, Connolly DJ, Rapson N, Jeal S, Brown JC, Kingsley GH, et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford, England). 2000;39(10):1139–46.

    CAS  Google Scholar 

  84. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66(11):1473–8.

    CAS  PubMed  Google Scholar 

  85. Enbrel. Prescribing Information: http://www.enbrel.com/pdf/enbrel_pi.pdf. 2009.

  86. Remicade. Prescribing Information: http://www.medversation.com/medversation/assets/PI_MedGuides_External/REMICADE_PI.pdf. 2009.

  87. SIMPONI. Prescribing Information: http://www.centocoraccessone.com/centocoraccessone/assets/simponi/SIMPONI.pdf. 2009.

  88. Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24(9):1733–44.

    CAS  PubMed  Google Scholar 

  89. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466–8.

    CAS  PubMed  Google Scholar 

  90. Kaschka WP, Theilkaes L, Eickhoff K, Skvaril F. Disproportionate elevation of the immunoglobulin G1 concentration in cerebrospinal fluids of patients with multiple sclerosis. Infect Immun. 1979;26(3):933–41.

    CAS  PubMed  Google Scholar 

  91. Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier. J Neurochem. 2002;81(1):203–6.

    CAS  PubMed  Google Scholar 

  92. Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol dis. 2004;16(1):1–13.

    CAS  PubMed  Google Scholar 

  93. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood–brain barrier. J Neuroimmunol. 2001;114(1–2):168–72.

    CAS  PubMed  Google Scholar 

  94. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood–brain barrier neonatal Fc receptor. J Neurosci. 2005;25(50):11495–503.

    CAS  PubMed  Google Scholar 

  95. Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood–brain barrier and Abeta fibril disaggregation. Bioconjug Chem. 2007;18(2):447–55.

    CAS  PubMed  Google Scholar 

  96. Avastin. Prescribing Information: http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. 2009.

  97. Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol. 2008;26(6):1012–3. author reply 3.

    PubMed  Google Scholar 

  98. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–9.

    CAS  PubMed  Google Scholar 

  99. Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics. 2009;6(3):447–57.

    CAS  PubMed  Google Scholar 

  100. Rascher G, Fischmann A, Kroger S, Duffner F, Grote EH, Wolburg H. Extracellular matrix and the blood–brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. 2002;104(1):85–91.

    CAS  PubMed  Google Scholar 

  101. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood–brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68(21):1809–14.

    CAS  PubMed  Google Scholar 

  102. Bapineuzumab. http://www.wyeth.nl/Portals/0/downloads/pers/persberichten/Bapi%20P2%20FINAL%20 -- %2028July08.pdf. 2008.

  103. Nadler LM, Korsmeyer SJ, Anderson KC, Boyd AW, Slaughenhoupt B, Park E, et al. B cell origin of non-T cell acute lymphoblastic leukemia a model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest. 1984;74(2):332–40.

    CAS  PubMed  Google Scholar 

  104. Rosenthal P, Rimm IJ, Umiel T, Griffin JD, Osathanondh R, Schlossman SF, et al. Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol. 1983;131(1):232–7.

    CAS  PubMed  Google Scholar 

  105. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678–85.

    CAS  PubMed  Google Scholar 

  106. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–33.

    CAS  PubMed  Google Scholar 

  107. Vugmeyster Y, Howell K. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int Immunopharmacol. 2004;4(8):1117–24.

    CAS  PubMed  Google Scholar 

  108. Vugmeyster Y, Howell K, Bakshl A, Flores C, Canova-Davis E. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A. 2003;52(2):101–9.

    PubMed  Google Scholar 

  109. Vugmeyster Y, Howell K, McKeever K, Combs D, Canova-Davis E. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int Immunopharmacol. 2003;3(10–11):1477–81.

    CAS  PubMed  Google Scholar 

  110. Bornstein GG, Queva C, Tabrizi M, van Abbema A, Chavez C, Wang P, et al. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs. 2009. doi:10.1007/s10637-009-9291-z.

Download references

Acknowledgments

The material presented in this article was partly used as teaching aid during the Fourth and Fifth Annual Protein Engineering Summit, PEGS (2008, and 2009), and the Molecular Medicine TriMolecular Conference, MMTC, (2009).

Author information

Authors and Affiliations

  1. Preclinical Development (MT) and Corporate Development (HS), AnaptysBio, Inc., 10835 Road to the Cure, Suite 100, San Diego, California, 92121, USA

    Mohammad Tabrizi & Hamza Suria

  2. Cancer Biologics, Astrazeneca R&D Boston, PLC, 35 Gatehouse Drive, Waltham, Massachusetts, 02451, USA

    Gadi Gazit Bornstein

Authors
  1. Mohammad Tabrizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gadi Gazit Bornstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hamza Suria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Tabrizi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tabrizi, M., Bornstein, G.G. & Suria, H. Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease. AAPS J 12, 33–43 (2010). https://doi.org/10.1208/s12248-009-9157-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-009-9157-5

Key words

Search

Navigation